GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BillionToOne BLLN · USD

Health Care · US listing · 🇺🇸 United States

Compare

89.92

-0.31%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

BillionToOne — daily BLLN Delayed
Market value
$4.12bn
Last close × shares
Volume
819.5k
Shares, 20 Nov 2026
Price to earnings
699.3

About BillionToOne

From its filings with the US Securities and Exchange Commission

SEC filings

BillionToOne is based in Menlo Park, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BLLN. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $305.1m and net income of $7.5m. At that date it held total assets of $632.7m and shareholders' equity of $480.1m.

In its own words

BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule next-generation sequencing (smNGS) platform achieves what was once thought impossible—detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented Quantitative Counting Templates (QCTs), enabling measurements at the physical limit of detection—the single DNA molecule. This leap forward addresses a fundamental limitation in healthcare—the inability to detect sparse but clinically crucial disease signals in cell-free DNA (cfDNA).

Our superior technology platform has enabled us to build category-defining prenatal and oncology products. Our products reveal actionable insights from a simple blood draw that are fundamentally changing how diseases are diagnosed and treated, leading to a paradigm shift in personalized medicine, overcoming the technical noise that restrains the traditional next-generation sequencing (NGS) testing methods used by other diagnostic companies. We believe our novel smNGS platform technologies combined with our AI-enhanced integrated workflow, allows us to push the technology frontier forward and deliver on the full promise of non-invasive liquid biopsy.

Quoted from its 10-K, filed 11 Mar 2026. Read the filing on SEC.gov ↗

More about BillionToOne →

Latest on BillionToOne

Our reporting

Next results

3 Mar 2027

Due on 3 Mar 2027. Analysts expect earnings of 0.16 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is BillionToOne's ticker?

BillionToOne trades as BLLN on its US listing, under ISIN US0901681058.

What was BillionToOne's last closing price?

89.92 on 20 Nov 2026. The figure is in USD and is never converted.

When does BillionToOne next report results?

Results are expected on 10 Mar 2027, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.